Berislav Spahija, MD
Neurology · Bismarck, NDNPI 1487606067
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 51 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $534 and has fallen 59.7% since, to $215 in 2025.
Across 51 payments — averaging $22.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$123
- AbbVie$119
- AstraZeneca$115
- Amgen$110
- Lilly USA, LLC$100
- Lundbeck LLC$86
- plus $502 from 19 others
What the payments were for
- Food & beverage$1,155100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 7 | $123 |
| AbbVie(2 entities) | 5 | $119 |
| AstraZeneca | 4 | $115 |
| Amgen | 3 | $110 |
| Lilly USA, LLC | 2 | $100 |
| Lundbeck LLC | 2 | $86 |
| UCB, Inc. | 3 | $57 |
| Acadia Pharmaceuticals Inc | 3 | $55 |
| Sanofi | 3 | $47 |
| Bristol Myers Squibb | 2 | $41 |
| Biohaven Pharmaceuticals, Inc. | 1 | $40 |
| Tersera Therapeutics LLC | 2 | $33 |
| Biogen | 2 | $26 |
| Radius Health, Inc. | 1 | $25 |
| Catalyst Pharmaceuticals, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Springworks Therapeutics, Inc. | 1 | $19 |
| Medtronic | 1 | $19 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Pfizer | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Tanabe Pharma America, Inc. | 1 | $13 |
| GE HealthCare | 1 | $11 |
| Adamas Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$1,155 in reported general payments places this provider in the 70th percentile of 39 neurology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 25 | $2,392 |
| Levetiracetam | 46 | $1,327 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 53 | $930 |
| Zonisamide | 33 | $692 |
| Lamotrigine | 11 | $445 |
| Primidone | 14 | $228 |
| Duloxetine Hcl | 11 | $139 |
| Donepezil Hcl | 12 | $114 |
Paid to pharmacies, not to this prescriber.
Other neurology in Bismarck
- Jess MillerBismarck$2K
- Ralph DunniganBismarck$2K
- John RiedingerBismarck$2K
- Jason DuchschererBismarck$773
- Stephanie MillerBismarck$621
- Chatree WongjiradBismarck$432
- Siriwan KriengkrairutBismarck$125
- Tanya HarlowFargo$73K
- Susan ScarberryFargo$67K
- Sarah KendroudFargo$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.